home About Senju Pharmaceutical R & D / production system This is the watchword of us researchers. Senju Pharmaceutical has its own research system, such as international joint research and industry-academia collaborative research, and is challenging research and development with flexible ideas without being bound by conventional excitement and stereotypes. Looking to the future, it is our goal and wish to quickly develop the safe medicines that are really needed. Senju Pharmaceutical conducts in-house animal experiments in accordance with the Ministry of Health, Labor and Welfare's "Basic Guidelines for Animal Experiments, etc." so that animal experiments are properly conducted from the viewpoint of experimental animal welfare in animal experiments conducted in the process of drug development. The committee conducts strict examination and monitoring, and at the same time, provides researchers with compliance with laws and guidelines of each ministry and agency, and education on laboratory animal ethics. In planning and implementing animal experiments, we are working on the practice of 4Rs, which includes the basic principles of 3Rs and the corporate responsibility of a pharmaceutical company, Responsibility. In June 2014, the Cove Creative Center acquired full certification from AAALAC International * , an international third-party evaluation organization . * 3 Rs principle 1.Reduction (reduction of the number of animals used in the experiment) 2.Refinement (reduction of pain suffered by animals) 3.Replacement (replacement for non-animal research) * AAALAC International (the Association for Assessment and Accreditation of Laboratory Animal Care International): A non-profit organization that provides international certification for laboratory animal management and use programs, where animal testing is scientific. It is an organization that investigates and certifies whether it is ethically implemented. Senju Pharmaceutical's R & D activities Kobe Creative Center コーベクリエイティブセンターでは、全世界にある医薬品候補化合物の中から、緑内障などの眼疾患治療に有効な化合物をスクリーニングしています。スクリーニング試験の結果に基づいて決定した候補化合物の臨床試験を開始するために必要な薬理試験、安全性試験、薬物動態試験、製剤化試験などの基礎データを法規制に基づいて取得しています。 所在地 オキュラーサイエンス研究所 オキュラーサイエンス研究所の使命は、最先端の技術と情報を駆使して、眼疾患の原因となる分子を同定し、それらを利用して千寿オリジナルの眼科薬を創製することです。そのため、神戸研究室と米国のオレゴン研究室との二研究室体制で連携し、研究を行っています。 神戸研究室 神戸医療産業都市構想の中心であるポートアイランド2期地区の神戸バイオメディカル創造センター（BMA）に神戸研究室を開設しております。神戸空港と、 神戸市中心部への中間というロケーションで、眼科疾患に対する治療薬開発のため基礎研究の中心部門としての機能を果たしております。この地区は、関西にお ける医療産業クラスターの中心部に位置し、研究を推進するに適した環境であり、千寿製薬にとって、国際的な研究拠点になっています。 所在地 オレゴン研究室 For more than 10 years since opening a laboratory at Oregon Health & Science University in Oregon, USA, we have built a close joint research system with the university and conducted basic research in the field of ophthalmology. Has been promoted. Currently, for further research development, we have moved to the non-profit organization OTRADI (Oregon Translational Research and Development Institute) Bioscience Incubator, and while maintaining the cooperation system with the university, we have created an environment where we can conduct basic research with more development awareness. I was there. By setting up a research department in the United States, it also plays an important role as a base for internationalization. location top message Management Philosophy Social and environmental initiatives Company Profile Trends in sales and ordinary income History Business introduction Medical drugs Over-the-counter drugs Veterinary drugs Cosmetic ingredients R & D / production system Research and Development production Global expansion List of offices / subsidiaries You can see the company profile in PDF. [PDF: 8MB]